Compare Summit Therapeutics Inc (SMMT) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.98B), while T Rowe Price Group Inc trades at $107.71 (market cap $22.98B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.83% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TROW | |
|---|---|---|
Market Cap | $13.98B | $22.98B |
Sector | Health | Financials |
52-Week High | $26.38 | $121.68 |
52-Week Low | $12.43 | $86.19 |
Enterprise Value | $13.31B | $20.18B |
Dividend Yield | — | 4.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal and key support at $109. The stock shows strong profitability with a net margin of 29.26% and ROE of 20.1%, supported by recent earnings beats in Q1 and Q2 2026. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and ongoing AI adoption, positioning the firm for growth amid equity outflows.
The outlook is mixed: valuation metrics like a P/E of 10.99 suggest potential upside to the $111.67 consensus target, but bearish technicals and analyst caution (63% hold rating) indicate near-term headwinds. Risks include market-sensitive revenue and competitive pressures, though dividend stability and institutional buying support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
